Anti-Mouse CD27 Antibody (RM27-3E5) 

Anti-Mouse CD27 Antibody (RM27-3E5) is an agonistic rat-derived IgG2a κ type antibody, targeting to mouse CD27. Anti-Mouse CD27 Antibody (RM27-3E5) stimulates CD 27. Anti-Mouse CD27 Antibody (RM27-3E5) can be used for the researches of cancer and immunology, such as B16cOVA tumor^[1][2].

Rat IgG2a kappa

Rat IgG2a kappa, Isotype Control

Mouse

CD27

The antibody framework is stable, specific and adaptable, and has the ability to bind both antigens and endogenous immune receptors. Monoclonal antibodies have several derivatives, including bispecific antibodies, antibody-drug conjugates, and antibody fragments, and have significant effects in fields such as immunology and oncology. When designing inhibitory antibodies, considerations include identification of antigen-specific variable regions, choice of expression system, use of multispecific formats, and antibody derivatives based on fragmentation, oligomerization, or conjugation with other functional moieties^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anti-Mouse CD27 Antibody (RM27-3E5) (100 μg, i.p., every 3-4 days from day 7) reduces tumor nodules in B16cOVA/B16F1 experimental tumor metastases mice models^[1].
Anti-Mouse CD27 Antibody (RM27-3E5) (100 μg, i.p., at days 5, 8, and 11) enhances cytotoxic T lymphocytes response and antitumor immunity companied with anti-CTLA-4/anti-PD-1 in TC-1 tumor mice models^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

21940  [NCBI]

P41272

in vivo CD27 stimulation; in vitro CD27 stimulation; Immunoprecipitation; Flow cytometry

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

150 kDa

[Anti-Mouse CD27 Antibody (RM27-3E5)]

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Roberts DJ, et al. Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells. J Immunother. 2010 Oct;33(8):769-79.  [Content Brief]

  [2]. Ahrends T, et al. CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination. Cancer Res. 2016 May 15;76(10):2921-31.  [Content Brief]